收费全文 | 49500篇 |
免费 | 3208篇 |
国内免费 | 945篇 |
耳鼻咽喉 | 374篇 |
儿科学 | 1263篇 |
妇产科学 | 1310篇 |
基础医学 | 5585篇 |
口腔科学 | 864篇 |
临床医学 | 4299篇 |
内科学 | 11730篇 |
皮肤病学 | 813篇 |
神经病学 | 4493篇 |
特种医学 | 1753篇 |
外国民族医学 | 2篇 |
外科学 | 6528篇 |
综合类 | 2101篇 |
现状与发展 | 1篇 |
一般理论 | 4篇 |
预防医学 | 2872篇 |
眼科学 | 659篇 |
药学 | 4127篇 |
8篇 | |
中国医学 | 970篇 |
肿瘤学 | 3897篇 |
2023年 | 431篇 |
2022年 | 1106篇 |
2021年 | 1727篇 |
2020年 | 1095篇 |
2019年 | 1223篇 |
2018年 | 1359篇 |
2017年 | 1091篇 |
2016年 | 1127篇 |
2015年 | 1443篇 |
2014年 | 1901篇 |
2013年 | 2398篇 |
2012年 | 3139篇 |
2011年 | 3179篇 |
2010年 | 1940篇 |
2009年 | 1726篇 |
2008年 | 2715篇 |
2007年 | 2741篇 |
2006年 | 2532篇 |
2005年 | 2387篇 |
2004年 | 2169篇 |
2003年 | 1901篇 |
2002年 | 1716篇 |
2001年 | 1437篇 |
2000年 | 1351篇 |
1999年 | 1265篇 |
1998年 | 479篇 |
1997年 | 363篇 |
1996年 | 377篇 |
1995年 | 295篇 |
1994年 | 271篇 |
1993年 | 234篇 |
1992年 | 686篇 |
1991年 | 587篇 |
1990年 | 547篇 |
1989年 | 556篇 |
1988年 | 464篇 |
1987年 | 421篇 |
1986年 | 409篇 |
1985年 | 324篇 |
1984年 | 269篇 |
1983年 | 221篇 |
1982年 | 130篇 |
1981年 | 104篇 |
1979年 | 216篇 |
1978年 | 139篇 |
1977年 | 115篇 |
1974年 | 125篇 |
1973年 | 131篇 |
1972年 | 123篇 |
1971年 | 112篇 |
Area covered: The current review is provided to update recent developments in the clinical application of cyclin/CDK inhibitors to breast cancer with a focus on the anti-tumor immune response.
Expert opinion: The cyclin D1 gene encodes the regulatory subunit of a proline-directed serine-threonine kinase that phosphorylates several substrates. CDKs possess phosphorylation site selectivity, with the phosphate-acceptor residue preceding a proline. Several important proteins are substrates including all three retinoblastoma proteins, NRF1, GCN5, and FOXM1. Over 280 cyclin D3/CDK6 substrates have b\een identified. Given the diversity of substrates for cyclin/CDKs, and the altered thresholds for substrate phosphorylation that occurs during the cell cycle, it is exciting that small molecular inhibitors targeting cyclin D/CDK activity have encouraging results in specific tumors. 相似文献
Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献Objective
To discover the experiences of end-of-life patients attended by the emergency services, through the discourse of the family caregivers who accompanied the family member in this care transit.Method
A qualitative approach study, based on the paradigm of hermeneutical phenomenology. In total, 81 family caregivers participated. The techniques used were the in-depth interview and the discussion group, with a total of 5 discussion groups and 41 interviews. The period of data collection was carried out between January 2013 and June 2014.Results
In the network of discourses obtained with respect to “Urgent Care”, all the codes were grouped in relation to a single argumentative line: deficiencies in urgent care. Among them, we found different dimensions that are established depending on the different times of care, or the different determinant aspects of these deficiencies: disorganization of the care received, lack of experience of the professionals in emergencies, application of general protocols in the emergency services, inadequate care in the treatment received, delays in emergency care.Conclusions
In general, we highlight the dissatisfaction of the family members with respect to the care received from the emergency services. The needs of these types of situation are not covered from these services and are of low quality. Therefore, it is necessary to reorient the care protocols for these patients. 相似文献Patients and methods: Within 1 year, all consecutive patients seen in our department for HS (1) resistant to usual medical therapies (2) which could not be easily cured by surgery (3) not treated with new medication within 2 months before inclusion were treated intravenously with infliximab (5 mg/kg) without corticosteroids premedication. Four infusions were planned (week 0, week 2, week 6 and week 10) before the interruption of therapy and follow-up. Clinical activity of HS and quality of life of the patients were assessed immediately before the first, the third and the fourth infusions of infliximab.
Results: Seven patients were included. Five completed the four infusions. Two patients received only three infusions because of severe side effects. The Sartorius score moderately improved with infliximab (mean score at week 0: 94 ± 39, at week 6: 71 ± 38 and at week 10: 83 ± 48). At week 6, patients judged the efficacy of therapy as marked ( n = 1), moderate ( n = 4) or null ( n = 2). At week 10, five patients were evaluated and judged this efficacy as marked ( n = 2), moderate ( n = 2) or null ( n = 1). The mean Skindex-29 score varied from 22 ± 11 (E: 25 ± 9, S: 13 ± 5, F: 28 ± 12) at week 0 to 18 ± 10 (E: 22 ± 8, S: 12 ± 8, F: 22 ± 12) at week 10.
Conclusion: The efficacy of infliximab in severe HS is partial. More experience is needed before finding a place for infliximab in the therapeutic armamentarium for HS. 相似文献